Empagliflozin fails to reduce HF hospitalizations, deaths after acute MI: EMPACT-MI
A study called EMPACT-MI found that empagliflozin, a drug used to treat type 2 diabetes, did not reduce the risk of heart failure hospitalizations or deaths after a heart attack. The study results suggest that empagliflozin may not be effective in improving outcomes for patients with acute myocardial infarction. This information is important for healthcare…